DARE Stock - Daré Bioscience, Inc.
Unlock GoAI Insights for DARE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9,784 | $2.81M | $10.00M | N/A | N/A |
| Gross Profit | $-14,295,424 | $-18,830,189 | $-20,142,217 | $-100,000 | $-83,333 |
| Gross Margin | -146110.2% | -670.6% | -201.4% | N/A | N/A |
| Operating Income | $-23,451,485 | $-30,939,880 | $-31,385,488 | $-39,068,512 | $-27,402,257 |
| Net Income | $-4,053,599 | $-30,161,391 | $-30,947,738 | $-38,696,105 | $-27,400,743 |
| Net Margin | -41430.9% | -1074.2% | -309.5% | N/A | N/A |
| EPS | $-0.48 | $-4.15 | $-4.39 | $-7.52 | $-10.93 |
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
Visit WebsiteEarnings History & Surprises
DAREEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.31 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.33 | $-0.28 | +15.2% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.55 | $-0.45 | +18.2% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.63 | $-0.50 | +20.6% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.66 | $-0.64 | +3.0% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.60 | $-0.55 | +8.3% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.57 | $1.52 | +366.7% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.72 | $-0.84 | -16.7% | ✗ MISS |
Q4 2023 | Dec 30, 2023 | — | $-0.69 | — | — |
Q4 2023 | Nov 9, 2023 | $-1.20 | $-1.08 | +10.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-1.20 | $-1.20 | 0.0% | = MET |
Q2 2023 | May 11, 2023 | $-1.20 | $-1.08 | +10.0% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-1.80 | $-2.28 | -26.7% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-1.32 | $-0.96 | +27.3% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.06 | $0.06 | +197.0% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-1.68 | $-1.20 | +28.6% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-2.52 | $-2.16 | +14.3% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-1.32 | $-2.16 | -63.6% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-1.80 | $-2.16 | -20.0% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-2.76 | $-1.92 | +30.4% | ✓ BEAT |
Latest News
Dare Bioscience shares are trading higher after the company announced it launched its first evidence-backed topical Sildenafil Cream for women.
📈 PositiveDaré Bioscience Launches First Evidence-Backed Topical Sildenafil Cream For Women
📈 PositiveHC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $12 Price Target
📈 PositiveDaré Bioscience Receives About $3.6M Payment Under Existing Grant Agreement With Gates Foundation
📈 PositiveDare Bioscience Q3 EPS $(0.28) Beats $(0.39) Estimate, Sales $2.262K Miss $9.750K Estimate
➖ NeutralDaré Bioscience To Host Webinar Titled 'The DARE to PLAY Difference' On Nov. 17
➖ NeutralDaré Bioscience Secures Gates Foundation Contract Worth Up To $300K To Conduct A Strategic Landscape Review Of Organizations With Capabilities Relevant To Contraceptive Product Development
📈 PositiveDaré Bioscience Secures Up To ~$499K From Gates Foundation To Support Preeclampsia Research Through Mentorship And Project Management
📈 PositiveMaxim Group Upgrades Dare Bioscience to Buy, Announces $8 Price Target
📈 PositiveFrequently Asked Questions about DARE
What is DARE's current stock price?
What is the analyst price target for DARE?
What sector is Daré Bioscience, Inc. in?
What is DARE's market cap?
Does DARE pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DARE for comparison